LONDON--(BUSINESS WIRE)--MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today that it has completed an exclusive license agreement with The Regents of the University of California relating to intellectual property rights developed by the Li lab at UC San Francisco (UCSF). The exclusive license complements MiNA’s fundamental intellectual property portfolio that broadly covers RNAa therapeutics, including small activating RNAs, or saRNAs, the molecules that mediate RNAa.
Help employers find you! Check out all the jobs and post your resume.
